Koers PharmaRoth Labs, Inc. Other OTC
Aandelen
ROTH
US71715Y1029
Farmaceutische producten
Omzet 2009 | - | Omzet 2010 | - | Marktkapitalisatie | 5,74 mln. 5,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2009 | - 0 | Nettowinst (verlies) 2010 | - 0 | EV/omzet 2009 | - |
Nettoschuld 2009 | 12,5K 11,53K | Nettoschuld 2010 | 286K 264K | EV/omzet 2010 | - |
K/w-verhouding 2009 |
-777
x | K/w-verhouding 2010 |
-7,8
x | Werknemers | - |
Dividendrendement 2009 * |
-
| Dividendrendement 2010 |
-
| Vrij verhandelbaar | 30,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 31-08-10 | |
Barry W. Hall
DFI | Director of Finance/CFO | 76 | 22-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 31-08-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+32,36% | 694 mld. | |
+30,00% | 593 mld. | |
-1,60% | 371 mld. | |
+20,07% | 331 mld. | |
+6,04% | 290 mld. | |
+14,66% | 239 mld. | |
-3,23% | 209 mld. | |
+10,22% | 209 mld. | |
+9,27% | 169 mld. |